Evidence map›Paper›PMID 40971112›Full record

ReviewPain and therapy2025

Neurotransmitter Imbalance in Cluster Headache: A Systematic Review of Mechanisms and Therapeutic Targets.

Lanfranco Pellesi, Anas Mohammad, Wei Wang, Paolo Martelletti

Abstract readReview
In one paragraph

Review in Pain and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lanfranco PellesiClinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense, Denmark. lpellesi@health.sdu.dk.ORCID http://orcid.org/0000-0003-4137-5039
Anas MohammadClinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense, Denmark.
Wei WangDepartment of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0000-0003-2302-6273
Paolo MartellettiSchool of Health, Unitelma Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-6556-4128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCluster headache (CH) causes brief but extremely severe head pain, yet we still do not fully understand the molecules that trigger these attacks. Many studies have looked at changes in neurotransmitters and neuropeptides, but their results do not always agree. This systematic review brings together all the available data on neurochemical changes in CH, with the goal of clarifying current knowledge gaps and highlighting promising targets for future research.

methodsWe searched PubMed, Embase (Ovid), and Scopus for studies reporting quantitative measurements of neurotransmitters in human biological samples from individuals with CH, as well as provocation studies in which neurotransmitters or neurotransmitter-related compounds were administered to trigger attacks. Thirty-eight eligible studies were identified. For each, we extracted information on design, participant characteristics, sampling matrix (e.g., plasma, saliva, cerebrospinal fluid, platelets), and the neuromodulators assayed, and then synthesized the findings narratively.

resultsAltered levels of histamine and sensory neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P were documented, especially during active headache attacks. Conflicting data were reported for serotonin, whereas nitric oxide (NO), pituitary adenylate cyclase-activating peptide (PACAP), and vasoactive intestinal peptide (VIP) provoked CH attacks in experimental studies. Data on orexins and their receptors were inconclusive.

conclusionsThe evidence emphasize several potential therapeutic targets, including CGRP, substance P, histamine, VIP, and PACAP. However, interpretation is hampered by heterogeneity across studies and methodological limitations, particularly the large variance and uncertainties of CGRP assays, which make cross-study comparisons difficult. Further research is needed to elucidate the exact molecular mechanisms driving CH and to identify effective therapeutic interventions.

Indexed as

BiomarkerCGRPMigraineOrexinsPACAPPainSerotoninSubstance P

Identifiers

PMID40971112
PMCPMC12634951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.